SCHEMBL437130

SCHEMBL437130

NOCc1cscn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1715857 0.98
SCHEMBL2094252 0.77
SCHEMBL18513675 0.77
SCHEMBL3999262 0.74 PKM (0.45)
SCHEMBL13327033 0.74 ALDH1A1 (0.38)
SCHEMBL531638 0.74 ALDH1A1 (0.38)
SCHEMBL1190495 0.73
SCHEMBL12530505 0.72 SLC6A3 (0.37)
SCHEMBL1358804 0.72
Hydrochloric Acid SCHEMBL6941733 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022040110-A2 ALKYLATING AGENT AND COMBINATIONS IN THE TREATMENT OF IMMUNE-RELATED AND LIVER DISEASES, ALZHEIMER'S DISEASES AND FIBROSIS DISEASES LIU SHENG (US) 2022-02-24 WO claimed
US-10722530-B2 Methods of diagnosing and treating cancer CASE WESTERN RESERVE UNIVERSITY (US) 2020-07-28 US claimed
US-10725042-B2 Methods of diagnosing and treating cancer CASE WESTERN RESERVE UNIVERSITY (US) 2020-07-28 US claimed
US-20180185403-A1 METHODS OF DIAGNOSING AND TREATING CANCER CASE WESTERN RESERVE UNIVERSITY 2018-07-05 US claimed
US-20170071965-A1 ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER UNIV CASE WESTERN RESERVE (US) 2017-03-16 US claimed
US-9498489-B2 Antimetabolite agent combinations in the treatment of cancer CASE WESTERN RESERVE UNIVERSITY (US) 2016-11-22 US claimed
US-8716346-B2 Alkylating agent combinations in the treatment of cancer CASE WESTERN RESERVE UNIVERSITY (US) 2014-05-06 US claimed
US-20140066464-A1 METHODS OF DIAGNOSING AND TREATING CANCER CASE WESTERN RESERVE UNIVERSITY (US) 2014-03-06 US claimed
US-8324282-B2 Alkylating agent combinations in the treatment of cancer CASE WESTERN RESERVE UNIVERSITY (US) 2012-12-04 US claimed
US-20120065145-A1 ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER GERSON STANTON L (US) 2012-03-15 US claimed
US-20100267657-A1 ANTIMETABOLITE AGENT COMBINATIONS IN THE TREATMENT OF CANCER CASE WESTERN RESERVE UNIVERSITY 2010-10-21 US claimed
US-20070244117-A1 Novel Hydroxamic Acid Esters and Pharmaceutical Use Thereof LEO PHARMA A/S (DK) 2007-10-18 US claimed
JP-2007513098-A 2007-05-24 JP claimed
EP-1697312-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF Leo Pharma A/S (DK) 2006-09-06 EP claimed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO claimed
WO-2022040110-A2 ALKYLATING AGENT AND COMBINATIONS IN THE TREATMENT OF IMMUNE-RELATED AND LIVER DISEASES, ALZHEIMER'S DISEASES AND FIBROSIS DISEASES LIU SHENG (US) 2022-02-24 WO disclosed
EP-3455216-B1 PYRIDINYL DERIVATIVES, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF AS AOC3 INHIBITORS BOEHRINGER INGELHEIM INT (DE) 2020-11-04 EP disclosed
WO-2005054179-A2 HYDROXAMIC ACID ESTERS AND PHARMACEUTICAL USE THEREOF LEO PHARMA A/S (DK) 2005-06-16 WO disclosed
WO-2003070234-A9 ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER UNIV CASE WESTERN RESERVE (US) 2004-02-26 WO disclosed
WO-2003070234-A1 ALKYLATING AGENT COMBINATIONS IN THE TREATMENT OF CANCER CASE WESTERN RESERVE UNIVERSITY (US) 2003-08-28 WO disclosed